Navigation Links
Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
Date:5/1/2013

GERMANTOWN, Md., May 1, 2013 /PRNewswire/ -- Intrexon Corporation, a next generation synthetic biology company, today announced that it has closed a Series F preferred investment round of $150 million, bringing the company's total capital raised to $509 million. New investors accounted for the majority of the round, with current investors, including affiliates of Randal J. Kirk , Intrexon's Chairman and CEO, and Third Security, LLC, taking the balance of the round.

The funding will be used to provide working capital for the establishment of additional exclusive channel collaborations in Intrexon's core sectors, including Healthcare, Food, Energy and Environment, continued development of the company's industry-leading technology platforms, expansion of sales and marketing, and research and development. 

"The Intrexon team is committed to delivering results for all of our collaborations," said Mr. Kirk. "With our proprietary technology platforms, we are helping our collaborators discover, design, develop and ultimately bring to market genetically-enhanced products that hold remarkable promise."

Mr. Kirk added, "It is especially gratifying to our entire team that, in addition to being our largest investment series to date, a majority of the investment came from new investors who share our vision."

About Intrexon CorporationIntrexon Corporation is a privately held biotechnology company focused on the industrial engineering of synthetic biology.  Intrexon is deploying its extensive capabilities to rapidly design and produce novel and enhanced biological products and processes across multiple industry sectors, including: human therapeutics, protein production, industrial products, agricultural biotechnology, and animal science.  The company's advanced bioindustrial engineering platform enables Better DNA™ technology by combining revolutionary DNA control systems with corresponding advancements in modular transgene design, assembly, and optimization to enable unprecedented control over the function and output of living cells. More information about the Company is available at www.dna.com.

Safe Harbor StatementSome of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information regarding Intrexon Corporation, contact:Corporate Contact:Investor Contact:Marie L. Rossi, Ph.D.The Ruth GroupManager, Technical Communications Intrexon Corporation

Tel: +1 301-556-9944

mrossi@intrexon.com

 Stephanie Carrington / Nicole Greenbaum

Tel: +1 646-536-7017/7009

scarrington@theruthgroup.com

ngreenbaum@theruthgroup.com 

 


'/>"/>
SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
2. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
3. Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013
4. Techne Corporation Releases Unaudited Third Quarter And Nine Month Fiscal Year 2013 Results
5. Street Named After EMCO High Voltage Corporation
6. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
7. Celsion Corporation Provides Business Update
8. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
9. EMCO High Voltage Corporation to Exhibit at Del Mar Electronics & Design Show
10. LamdaGen Corporation Announces Japan Patent Issuance for Enzymatic Diagnostic Assays on Plasmonic Nano-Sensors
11. Centene Corporation Completes Acquisition Of Specialty Pharmacy Leader AcariaHealth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... ... FireflySci Inc. is a go-getter type of company that continues to grow ... main factors. The first is the amazing customer service that the FireflySci staff ... around the world. , 2016 was a tremendous sales year for FFS and much ...
(Date:1/19/2017)... 2017 Acupath Laboratories, Inc., a leading provider ... an Executive Committee that will guide the company,s vision ... John Cucci , a 15-year veteran of the anatomic ... Development to Chief Sales Officer .  Prior to ... senior sales leadership roles at several leading lab industry ...
(Date:1/18/2017)... --  Boston Biomedical , an industry leader in the ... pathways, will feature data from two clinical studies for ... Gastrointestinal Cancers Symposium, held from January 19-21, in ... is an orally-administered investigational agent designed to inhibit cancer ... cells (CSCs) possess the property of stemness – the ...
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics and ... SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, 2017 at ... was an anterior cervical discectomy and fusion on a 42 year old female ...
Breaking Biology Technology:
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/11/2017)... Jan. 11, 2017 Intoxalock, a leading ignition ... release of its patent-pending calibration device. With this new ... calibrations, securely upload data logs and process repairs at ... "Fighting drunk driving through the application of ... at large, but also for the customer who can ...
Breaking Biology News(10 mins):